SCHEMBL424347

SCHEMBL424347

COc1ccc(-c2ncn(C(=O)N(C)c3ccccc3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 5/20 0.56
ACHE P22303 4/20 0.56
KDM4E B2RXH2 2/20 0.44
MGLL Q99685 2/20 0.44
BCHE P06276 1/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
ALOX12 P18054 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427521 0.88 ACHE (0.47) LIPEACHEMGLLBCHEKMT2A
SCHEMBL425582 0.85 PARP10 (0.47) LIPEACHEMGLLALDH1A1KMT2A
SCHEMBL427271 0.85 LIPE (0.58) LIPEACHEMGLLALDH1A1NPSR1
SCHEMBL7898089 0.84 ACHE (0.45) LIPEACHEKDM4EMGLLHPGD
SCHEMBL426694 0.77 ACHE (0.49) LIPEACHEKDM4EHPGDALDH1A1
SCHEMBL2179538 0.76 BCHE (0.48) LIPEACHEMGLLBCHEALDH1A1
SCHEMBL427439 0.74 ALDH1A1 (0.44) LIPEACHEKDM4EALDH1A1HTT
SCHEMBL427280 0.73 GPBAR1 (0.46) LIPEACHEMGLLBCHEKMT2A
SCHEMBL424517 0.73 SMN1; SMN2 (0.42) LIPEACHEKDM4EHPGDALDH1A1
SCHEMBL425544 0.72 FAAH (0.52) LIPEACHEALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 LIPE 61/4885ACHE 167/4885KDM4E 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.